Alligator Bioscience AB (publ) Interim report January-June 2019
Competitive safety data for ADC-1013.Significant events April-June• Janssen presented data from the clinical Phase I study with ADC-1013 indicates good safety and shows initial signs of clinical effect.• Study design and progress for the ongoing ATOR-1015 Phase I study showcased at ASCO.• Clinical trial authorization (CTA) application submitted to initiate a ATOR-1017 Phase I study.• New preclinical data presented at scientific conferences:- ATOR-1015:s tumor-localizing properties, shown with live-imaging technique, presented at PEGS (The Essential Protein Engineering Summit).-